Parkinson’s disease is an age-related neurodegenerative disorder. The major symptoms of Parkinson’s disease are closely linked to the pathology of the disease. The main pathology of Parkinson’s disease consists of the degeneration of neurons of the substantia nigra pars compacta (SNpc), which leads to reduced amounts of dopamine in the brain. One of the treatment strategies in Parkinson’s disease is to conserve dopamine by inhibiting the enzymes responsible for its catabolism. The monoamine oxidase (MAO) B isoform catalyses the oxidation of dopamine in the central nervous system and is therefore an important target for Parkinson’s disease treatment. Inhibition of MAO-B provides symptomatic relief for Parkinson’s disease patients by increasing endogenous dopamine levels as well as enhancing the levels of dopamine after administration of levodopa (L-dopa), the metabolic precursor of dopamine. Recent studies have shown that phthalide can be used as a scaffold for the design of reversible MAO inhibitors. Although phthalide is a weak MAO-B inhibitor, substitution on the C5 position of phthalide yields highly potent reversible MAO-B inhibitors. In the present study, sesamol and benzodioxane were used as scaffolds for the design of MAO inhibitors. The structures of sesamol and benzodioxane closely resemble that of phthalide, which suggests that these moieties may be useful for the design of MAO inhibitors. This study may be viewed as an exploratory study to discover new scaffolds for MAO inhibition. Since substitution at C5 of phthalide with a benzyloxy side chain yielded particularly potent MAO inhibitors, the sesamol and benzodioxane derivatives possessed the benzyloxy substituent in the analogous positions to C5 of phthalide. These were the C5 and C6 positions of sesamol and benzodioxane, respectively. The sesamol and benzodioxane derivatives were synthesised by reacting sesamol and 6- hydroxy-1,4-benzodioxane, respectively, with an appropriate alkyl bromide in the presence of potassium carbonate (K2CO3) in N,N-dimethylformamide (DMF). 6-Hydroxy-1,4- benzodioxane, in turn, was synthesised from 1,4-benzodioxan-6-carboxaldehyde. The structures of the compounds were verified with nuclear magnetic resonance (NMR) and mass spectrometry (MS) analyses, while the purities were estimated by high-pressure liquid chromatography (HPLC). Sixteen sesamol and benzodioxane derivatives were synthesised. To determine the inhibition potencies of the synthesised compounds the recombinant human MAO-A and MAO-B enzymes were used. The inhibition potencies were expressed as the corresponding IC50 values. The results showed that the sesamol and benzodioxane derivatives are highly potent and selective inhibitors of MAO-B and to a lesser extent MAOA. The most potent MAO-B inhibitor was 6-(3-bromobenzyloxy)-1,4-benzodioxane with an IC50 value of 0.045 μM. All compounds examined displayed selectivity for the MAO-B isoform over MAO-A. Generally the benzodioxane derivatives were found to be more potent inhibitors of human MAO-A and MAO-B than the sesamol derivatives. The reversibility and mode of MAO-B inhibition of a representative derivative, 6-(3- bromobenzyloxy)-1,4-benzodioxane, was examined by measuring the degree to which the enzyme activity recovers after dialysis of enzyme-inhibitor complexes, while Lineweaver- Burk plots were constructed to determine whether the mode of inhibition is competitive. Since MAO-B activity is completely recovered after dialysis of enzyme-inhibitor mixtures, it was concluded that 6-(3-bromobenzyloxy)-1,4-benzodioxane binds reversibly to the MAO-B enzyme. The Lineweaver-Burk plots constructed were linear and intersected on the y-axis. Therefore it may be concluded that 6-(3-bromobenzyloxy)-1,4-benzodioxane is a competitive MAO-B inhibitor. To conclude, the C6-substituted benzodioxane derivatives are potent, selective, reversible and competitive inhibitors of human MAO-B. These compounds are therefore promising leads for the future development of therapy for Parkinson’s disease. / MSc (Pharmaceutical Chemistry), North-West University, Potchefstroom Campus, 2015

Purpose: Monoamine oxidase (MAO) plays a key role in the treatment of Parkinson‟s disease (PD), since it is the major enzyme responsible for the catabolism of dopamine in the substantia nigra of the brain. Inhibition of MAO-B may conserve dopamine in the brain and provide symptomatic relief. The MAO-B inhibitors that are currently used for the treatment of PD, are associated with a variety of adverse effects (psychotoxic and cardiovascular effects) along with additional disadvantages such as irreversible inhibition of the enzyme. Irreversible inhibition may be considered a disadvantage, since following treatment with irreversible inhibitors, the rate by which the enzyme activity is recovered may be variable and may require several weeks. In contrast, following the administration of reversible inhibitors, enzyme activity is recovered when the inhibitor is cleared from the tissues. There exists therefore, a need to develop new reversible inhibitors of MAO-B which are considered to be safer than irreversible MAO-B inhibitors. Rationale: Recently discovered reversible MAO-B inhibitors include safinamide and (E)-8-(3-chlorostyryl)caffeine (CSC). Safinamide has a benzyloxy side chain, which is thought to be important for inhibition of MAO-B. CSC, on the other hand, consists of a caffeine moiety with a styryl substituent at C-8, which is also a critical feature for its inhibitory activity. In a previous study, the caffeine ring and the benzyloxy side chain were combined to produce a series of 8-benzyloxycaffeine analogues which proved to be potent new MAO-B inhibitors. In this study, caffeine was substituted with the phenoxymethyl functional group at C-8, instead of the benzyloxy moiety. The aim of this study was therefore to compare the MAO-B inhibition potencies of selected 8-(phenoxymethyl)caffeine analogues with the previously studied 8-benzyloxycaffeine analogues. In the current study, 8-(phenoxymethyl)caffeine (1) and nine 8-(phenoxymethyl)caffeine analogues (2-10) were synthesized and evaluated as inhibitors of recombinant human MAOA and –B. These analogues only differed in substitution on C3 and C4 of the phenoxymethyl phenyl ring. The substituents that were selected were halogens (Cl, F, and Br), the methyl group, the methoxy group and the trifluoromethyl group. These substituents are similar to those selected in a previous study where 8-benzyloxycaffeine analogues were evaluated as MAO inhibitors. This study therefore explores the effect that a variety of substituents on C3 and C4 of the phenoxymethyl phenyl ring will have on the MAO-A and –B inhibition potencies of 8-(phenoxymethyl)caffeine. Based on the results, additional 8-(phenoxymethyl)caffeine analogues with improved MAO-A and –B inhibition potencies will be proposed for investigation in future studies. Methods: The target, 8-(phenoxymethyl)caffeine, analogues were synthesized by reacting 1,3- dimethyl-5,6-diaminouracil with the appropriately substituted phenoxyacetic acid in the presence of a carbodiimide coupling agent. Ring closure was catalyzed in basic conditions and methylation of the resulting theophyline intermediates at C-7 was carried out with iodomethane. The structures and purities of all the target compounds were verified by NMR, MS and HPLC analysis. All of the 8-(phenoxymethyl)caffeine analogues were subsequently evaluated as MAO-A and –B inhibitors using the recombinant human enzymes. The inhibition potencies of the analogues were expressed as the IC50 values (concentration of the inhibitor that produces 50% inhibition). In addition, the time-dependency of inhibition of both MAO-A and –B was evaluated for two inhibitors in order to determine if these inhibitors interact reversibly or irreversibly with the MAO isozymes. A Hansch-type quantitative structure-activity relationship (QSAR) study was carried out in order to quantify the effect that different substituents on the phenyl ring of the 8-(phenoxymethyl)caffeine analogues have on MAO-B inhibition activity. Results: The results showed that among the test compounds, several analogues potently inhibited human MAO-B. The most potent inhibitor was 8-(3-bromophenoxymethyl)caffeine with an IC50 value of 0.148 μM toward human MAO-B. There were also inhibitors which displayed inhibition activities towards human MAO-A with IC50 values ranging from 4.59 μM to 34.0 μM. Compared to the 8-benzyloxycaffeine analogues, that were in general non-selective inhibitors, the 8-(phenoxymethyl)caffeine analogues, evaluated here, were selective for MAO-B. For example, 8-(3-bromophenoxymethyl)caffeine was found to be 141 fold more selective as an inhibitor of MAO-B than of MAO-A. Also, compared to the 8-benzyloxycaffeine analogues, the 8-(phenoxymethyl)caffeine analogues were slightly less potent MAO-B inhibitors. For example, 8-benzyloxycaffeine is reported to have an IC50 value of 1.77 μM for the inhibition of human MAO-B while 8-(phenoxymethyl)caffeine was found to have an IC50 value of 5.78 μM for the inhibition of human MAO-B. This study also shows that two selected analogues bind reversibly to MAO-A and –B, respectively, and that the mode of MAO-B inhibition is competitive for one representative compound. Qualitative inspection of the results revealed interesting structure-activity relationships. For the 8-(phenoxymethyl)caffeine analogues, bearing both the C3 and C4 substituents on the phenyl ring, the MAO-B activity significantly increases with halogen substitution. Furthermore, increased MAO-B inhibition was observed with increased electronegativity of the halogen substituent. To quantify these apparent relationships, a Hansch-type QSAR study was carried out. The results showed that the logarithm of the IC50 values (logIC50) correlated with Hansch lipophilicity (π) and the Swain-Lupton electronic (F) constants of the substituents at C-3 of the phenoxymethyl ring. The correlation exhibited an R2 value of 0.87 and a statistical F value of 13.6. From these results it may be concluded that electron-withdrawing substituents at C3 with a high degree of lipophilicity enhance MAO-B inhibition potency. These results are similar to those previously obtained for the series of 8-benzyloxycaffeine analogues. For this series, the MAO-B inhibition potencies correlated with the Hansch lipophilicity (π) and Hammett electronic (σ) constants of the substituents at C-3 of the benzyloxy ring. Similarly to the 8-(phenoxymethyl)caffeine analogues, electron-withdrawing substituents with a high degree of lipophilicity also enhance the MAO-B inhibition potencies of 8-benzyloxycaffeine analogues. / Thesis (M.Sc. (Pharmaceutical Chemistry))--North-West University, Potchefstroom Campus, 2011

L’Astyanax mexicanus est un poisson téléostéen utilisé dans les études de microévolution. Au sein de la même espèce, il existe plusieurs populations. Des poissons de surface (SF), vivant en banc dans les rivières d’Amérique Centrale et plusieurs populations cavernicoles (CF), vivant dans l’obscurité des grottes mexicaines. La majorité des populations cavernicoles sont indépendantes et ont dérivé des populations de surface depuis environ un million d’années. Les CF sont aveugles et dépigmentés. D’un point de vue comportemental, les CF ont, entre autres, perdu l’agressivité qui est un caractère important des SF. Ce travail caractérise finement les différences comportementales entre poissons de surface et cavernicoles, et analyse les modifications des circuits neuronaux qui sont à l’origine de la perte du comportement agressif chez les poissons cavernicoles. Les tests d’agressivité montrent que deux SF s’attaquent dix fois plus que deux CF. La distribution temporelle des attaques diffère également entre les populations. En effet, la majorité des attaques entre CF ont lieu lors des premières minutes du test, alors que chez les SF la fréquence des attaques augmente au cours du temps. L’étude de l’agressivité de SF rendu aveugle ou dans le noir montre que la perte d’agressivité chez les CF n’est pas due au phénotype aveugle. De plus, l’agressivité des poissons hybrides suggère que le comportement agressif des SF est génétiquement codé. Après des expériences pharmacologiques utilisant des composés interférant avec le système sérotoninergique ou soumettant les SF et les CF à différents régimes alimentaires, nous faisons l’hypothèse selon laquelle la perte d’agressivité des CF est une adaptation à la vie cavernicole, ceux-ci recherchant en permanence de la nourriture. En revanche, l’agressivité des SF est étroitement reliée à la hiérarchie existant au sein du banc, la dominance étant elle-même liée en partie à la concentration de la sérotonine présente au niveau du raphé. La concentration de sérotonine est inversement corrélée à l’agressivité. D’un point de vue neuroanatomique, l’organisation du système sérotoninergique est similaire entre les populations. Cependant, l’un des noyaux hypothalamiques est plus large chez les CF et contient plus de neurones. Par ailleurs, l’agressivité et le taux de sérotonine sont connus pour être inversement corrélés chez les vertébrés. De fait, des traitements pharmacologiques augmentant le taux de sérotonine diminuent l’agressivité des SF et modifient leur profil d’agressivité, mimant celui des CF. Cependant, le système sérotoninergique n’est pas le seul à être modifié dans le système nerveux des CF. En réalité, les dosages HPLC montrent que l’ensemble des systèmes aminergiques est amplifié chez les CF, conduisant à l’apparition d’un phénotype « hyper-aminergique ». Les études neuro-anatomiques et enzymologiques des systèmes sérotoninergiques et catécholaminergiques montrent que des variations du nombre de neurones et de l’activité des enzymes de dégradation des neurotransmetteurs aminergiques convergent vers cette amplification et sont à l’origine de ce phénotype. Par ailleurs, et en parallèle, les méthodes de transgénèses stables ont été testées chez l’Astyanax. Cette étude montre que l’utilisation des méganucléases et des transposons sont utilisables chez notre poisson modèle et permettent l’établissement de lignées transgéniques. Cet outil permettra de tester à l’avenir l’importance et la fonction des gènes d’intérêt lors du développement du système nerveux, ainsi que lors de la mise en place des comportements. / Astyanax mexicanus is a teleost fish model used for evolution studies. Among the same species, there are several populations of sighted surface fish (SF) that live in Mexican rivers and at least twenty nine populations of blind cavefish (CF) that live in perpetual darkness. Several of these cave populations are independently-evolved, and they derived from surface fish-like ancestors. CF have lost their eyes and their pigmentation, and they have also evolved a number of behavioral traits. Most CF populations have lost the aggressive behavior that is a trademark of their SF counterparts. Here we characterized behavioural differences between SF and CF and we investigated the modifications of neural networks responsible for the loss of aggressiveness in cavefish. We first characterized aggressive behavior in Astyanax. Using an “intruder assay”, we found that SF not only attack ten times more during a one hour period, but also show a significantly different pattern in the temporal distribution of their attacks: while two CF attack mostly during the first minutes, SF attack more and more frequently as time goes by during the test. Then we demonstrated that the loss of aggressiveness in CF is not due to their blind phenotype, and using hybrids and independently-evolved populations of CF we could suggest that aggressive behavior in SF is genetically-encoded. After pharmacological experiments using compounds modulating serotonin levels or using SF and CF receiving different food regimes, we hypothesized that the loss of aggressiveness of CF may correspond to an adaptation to cave life, as they spend most of their time looking for food. On the other hand, the aggressiveness of SF is closely connected to the hierarchy within the school, dominance itself being mainly due to the levels of serotonin in the raphe. Thus, serotonin levels are inversely correlated with agonistic behavior. Neuroanatomical analyses on SF and CF brains showed an identical organization of their serotonin neuronal networks, but one of the serotonergic hypothalamic nucleus was significantly larger in CF and contained more neurons. Treatments of embryos with cyclopamine, an inhibitor of Sonic hedgehog (Shh) signaling, showed that this enlargement is induced by the Shh signaling pathway, itself known to be amplified during the development of the CF. In fact, the serotonergic system is not only one that is changed in the nervous system of CF. HPLC measurements showed that all aminergic systems are amplified in CF, which show a sort of “hyper-aminergic” phenotype. Studies comparing the neuroanatomy of aminergic systems and the activity of amine-degrading enzymes between SF and CF showed that variations in both the number of neurons and the activity of degrading enzymes converge towards an amplification of aminergic neurotransmission and are responsible for the phenotype. In parallel, we established transgenesis methods in Astyanax. We showed that techniques using meganuclease or transposons are valuable with our fish species to generate transgenic lines. This tool will be used to test the importance and function of genes of interest in the development of the nervous system and associated behaviors.

<p>This thesis concerns the study of reaction mechanisms by means of kinetic isotope effects (KIEs). Studies of the nucleophilic bimolecular substitution (S_N2) reaction had the dual purpose of improving our fundamental understanding of molecular reactivity and assessing the ability of kinetic isotope effects to serve as mechanistic tools. The transition state of the S_N2 reaction between a cyanide ion and ethyl chloride in tetrahydrofuran was found to be reactant like and only slightly tighter than has been found previously for the same reaction in dimethyl sulphoxide. One conclusion was that the transition-state structure in this reaction was predicted fairly well by the theoretical calculations, even without solvent modelling. The S_N2 reactions between cyanide ions and <i>para</i>-substituted benzyl chlorides were found to have reactant-like transition states, of which the C_α-Cl bond was most influenced by the <i>para</i>-substitution. Theoretical calculations indicated that the chlorine KIEs could be used as probes of the substituent effect on the C_α-Cl bond if bond fission was not too advanced in the transition state. Furthermore, the nucleophile carbon ¹¹C/¹⁴C KIEs were determined for the reactions between cyanide ions and various ethyl substrates in dimethyl sulphoxide.</p><p>Precision conductometry was employed to estimate the aggregation status of tetrabutylammonium cyanide in tetrahydrofuran and in dimethyl sulphoxide, which is of interest as tetrabutylammonium cyanide is frequently used as the nucleophilic reagent in mechanistic investigations and synthetic reactions. The tendency for ion-pair formation was found to be very slight, significant, and very strong in dimethyl sulphoxide, water, and tetrahydrofuran, respectively. </p><p>The nitrogen kinetic isotope effect on monoamine oxidase B catalysed deamination of benzylamine was determined in an attempt to obtain conclusive evidence regarding the mechanism of the oxidation. Monoamine oxidase is an important drug target in connection with the treatment of, for example, depression and Parkinson’s disease, and knowledge on how the enzyme effects catalysis would facilitate the design of highly selective and efficient inhibitors.</p>

This thesis concerns the study of reaction mechanisms by means of kinetic isotope effects (KIEs). Studies of the nucleophilic bimolecular substitution (SN2) reaction had the dual purpose of improving our fundamental understanding of molecular reactivity and assessing the ability of kinetic isotope effects to serve as mechanistic tools. The transition state of the SN2 reaction between a cyanide ion and ethyl chloride in tetrahydrofuran was found to be reactant like and only slightly tighter than has been found previously for the same reaction in dimethyl sulphoxide. One conclusion was that the transition-state structure in this reaction was predicted fairly well by the theoretical calculations, even without solvent modelling. The SN2 reactions between cyanide ions and para-substituted benzyl chlorides were found to have reactant-like transition states, of which the Cα-Cl bond was most influenced by the para-substitution. Theoretical calculations indicated that the chlorine KIEs could be used as probes of the substituent effect on the Cα-Cl bond if bond fission was not too advanced in the transition state. Furthermore, the nucleophile carbon 11C/14C KIEs were determined for the reactions between cyanide ions and various ethyl substrates in dimethyl sulphoxide. Precision conductometry was employed to estimate the aggregation status of tetrabutylammonium cyanide in tetrahydrofuran and in dimethyl sulphoxide, which is of interest as tetrabutylammonium cyanide is frequently used as the nucleophilic reagent in mechanistic investigations and synthetic reactions. The tendency for ion-pair formation was found to be very slight, significant, and very strong in dimethyl sulphoxide, water, and tetrahydrofuran, respectively. The nitrogen kinetic isotope effect on monoamine oxidase B catalysed deamination of benzylamine was determined in an attempt to obtain conclusive evidence regarding the mechanism of the oxidation. Monoamine oxidase is an important drug target in connection with the treatment of, for example, depression and Parkinson’s disease, and knowledge on how the enzyme effects catalysis would facilitate the design of highly selective and efficient inhibitors.

Ο εγκέφαλος των θηλαστικών είναι αρκετά ευάλωτος στις επιδράσεις περιβαλλοντικών τοξινών, λόγω των ιδιαίτερων δομικών και λειτουργικών χαρακτηριστικών του. Η έκθεση σε μια νευροτοξίνη εκδηλώνεται συνήθως μέσω γνωστικών και συμπεριφορικών διαταραχών, που συνοδεύουν δυσμενείς νευροχημικές αλλαγές και καθορίζονται από το είδος, την ηλικία, το φύλο, το γενετικό προφίλ, τη δόση, την οδό και τη χρονική περίοδο έκθεσης. Ωστόσο, η χρόνια έκθεση σε ένα νευροτοξικό παράγοντα είναι δυνατόν να επάγει μη αναστρέψιμη νευρωνική βλάβη και εκφύλιση. Το αργίλιο (Al), που συνιστά το τρίτο σε αφθονία στοιχείο στη φύση, ασκεί ποικίλες νευροτοξικές επιδράσεις, ανάλογα με τη χημική μορφή του μετάλλου, τη δόση, την οδό και την περίοδο έκθεσης, ενώ αμφιλεγόμενη παραμένει η εμπλοκή του στην παθογένεια της νόσου του Alzheimer. Η αφλατοξίνη Β1 (AFB1) ανήκει στην ομάδα των μυκοτοξινών (δευτερογενής μεταβολίτης των μυκήτων του γένους Aspergillus), μολύνει καλλιέργειες και ζωοτροφές και αποτελεί ισχυρή ηπατοτοξίνη και ηπατοκαρκινογόνο. Εντούτοις, η νευροτοξικότητα της AFB1 είναι ελάχιστα μελετημένη και οι λίγες αναφορές που παρουσιάζουν την εκδήλωση συμπεριφορικών διαταραχών, αφορούν την έκθεση σε αναπτυξιακό στάδιο. Εκτενής και εντατική είναι τις τελευταίες δεκαετίες η έρευνα της νευροπροστατευτικής δράσης φαρμακευτικών φυτών και των βιοδραστικών συστατικών τους, με απώτερο στόχο την πρόληψη ή αντιμετώπιση της εγκεφαλικής δυσλειτουργίας που επάγεται από γενετικούς ή/και περιβαλλοντικούς παράγοντες. Ενδιαφέρον για τον ελλαδικό χώρο, λόγω της υψηλής εμπορικής του αξίας, έχει το καλλιεργούμενο φυτικό είδος Crocus sativus L., του οποίου οι στύλοι (κρόκος ή σαφράν) χρησιμοποιούνται στη διατροφή ως άρτυμα και η φαρμακευτική τους αξία έχει αναγνωριστεί εδώ και χιλιετίες. Στόχος της παρούσας διδακτορικής διατριβής ήταν να συμβάλλει στην έρευνα της νευροτοξικής δράσης του Al και της AFB1 και του νευροπροστατευτικού ρόλου των στύλων του C. sativus, εστιάζοντας σε παραμέτρους της μνημονικής λειτουργίας ενηλίκων μυών, της χολινεργικής/μονοαμινεργικής διαβίβασης και της οξειδωτικής/αντιοξειδωτικής κατάστασης του εγκεφάλου τους. ΜΕΘΟΔΟΙ: Σε αρσενικούς ενήλικες Balb-c μύες (n=7-10/ομάδα) χορηγήθηκε δια στόματος AlCl3 (50 mg/kg σωματικού βάρους/ημέρα) διαλυμένο στο κανονικό πόσιμο νερό για 5 εβδομάδες ή ενδοπεριτοναϊκά (i.p.) AFB1 (0.3 και 0.6 mg/kg σωματικού βάρους/ημέρα) για 4 ημέρες. Η ικανότητα εκχυλισμάτων των στύλων του C. sativus και της κροκετίνης, του κύριου βιοδραστικού μεταβολίτη των καροτενοειδών συστατικών (κροκίνες) του κρόκου, να προλαμβάνουν ή να ανατρέπουν τις βλαπτικές επιδράσεις του Al και της AFB1 στον εγκέφαλο των μυών, διερευνήθηκε ακολουθώντας τα εξής σχήματα χορήγησης: α) υδατικό/μεθανολικό εκχύλισμα κρόκου (60 mg/kg σωματικού βάρους/ημέρα) χορηγήθηκε i.p. τις τελευταίες 6 ημέρες της περιόδου χορήγησης του AlCl3 (50 mg/kg σωματικού βάρους/ημέρα στο πόσιμο νερό για 5 εβδομάδες), β) αφέψημα κρόκου (0.45 mg/mL) καταναλώθηκε για 2 εβδομάδες πριν τη χορήγηση AFB1 (0.6 mg/kg σωματικού βάρους/ημέρα i.p. τις τελευταίες 4 ημέρες της περιόδου χορήγησης του αφεψήματος), και γ) καθαρή κροκετίνη (4 mg/kg σωματικού βάρους/ημέρα) χορηγήθηκε i.p. για 3 ημέρες πριν ή μετά τη χορήγηση AFB1 (0.6 mg/kg σωματικού βάρους/ημέρα i.p. για 4 ημέρες). Μελετήθηκαν επίσης, οι επιδράσεις των προηγούμενων σχημάτων χορήγησης του αφεψήματος κρόκου και της κροκετίνης στον εγκέφαλο υγιών ενηλίκων μυών. Η ικανότητα μάθησης/μνήμης των μυών αξιολογήθηκε με τη δοκιμασία παθητικής αποφυγής. Η ενεργότητα της ακετυλοχολινεστεράσης [AChE, διαλυτές σε άλας (SS)/απορρυπαντικό (DS) ισομορφές], της βουτυρυλοχολινεστεράσης (BuChE, SS/DS ισομορφές) και της μονοαμινοξειδάσης (ΜΑΟ, -Α και -Β ισομορφές) προσδιορίστηκαν στον ολικό εγκέφαλο (-ce, πλην παρεγκεφαλίδας) και την παρεγκεφαλίδα, ως δείκτες της χολινεργικής και μονοαμινεργικής διαβίβασης, αντιστοίχως. Επίσης, μετρήθηκαν οι συγκεντρώσεις της μηλονικής διαλδεΰδης (MDA) και της ανηγμένης γλουταθειόνης (GSH), ως δείκτες της λιπιδικής υπεροξείδωσης και της αντιοξειδωτικής άμυνας, αντιστοίχως, των εγκεφαλικών ιστών. Με τη χρήση φασματομετρίας ατομικής απορρόφησης μετρήθηκαν τα επίπεδα Al στους εγκεφαλικούς ιστούς, ενώ, για πρώτη φορά, η κροκετίνη προσδιορίστηκε στον ολικό εγκέφαλο (-ce) των μυών μετά την i.p. χορήγηση εκχυλίσματος κρόκου, με HPLC ανάλυση. ΑΠΟΤΕΛΕΣΜΑΤΑ: Η μακρόχρονη πρόσληψη υψηλής δόσης AlCl3 μέσω του πόσιμου νερού οδήγησε σε εξασθένηση της μάθησης/μνήμης των μυών, σημαντική μείωση της ενεργότητας της AChE και BuChE, αύξηση της ενεργότητας των ισομορφών της ΜΑΟ του ολικού εγκεφάλου (-ce), αλλά αναστολή της ΜΑΟ-Β της παρεγκεφαλίδας, σημαντική αύξηση των επιπέδων MDA στον εγκέφαλο και μείωση της συγκέντρωσης GSH στους εγκεφαλικούς ιστούς. Συσσώρευση του μετάλλου καταγράφηκε στους εγκεφαλικούς ιστούς των μυών που λάμβαναν AlCl3. Μνημονικό έλλειμμα εμφάνισαν οι μύες που έλαβαν την υψηλή (0.6 mg/kg) αλλά όχι χαμηλή δόση (0.3 mg/kg) AFB1. Επίσης, η βραχύχρονη i.p. χορήγηση της μυκοτοξίνης ανέστειλε τις χολινεστεράσες (ChEs), ενεργοποίησε τη ΜΑΟ, αύξησε σημαντικά τη λιπιδική υπεροξείδωση και μείωσε τα επίπεδα GSH στους εγκεφαλικούς ιστούς. Ωστόσο, διαφορική απόκριση στην έκθεση στην AFB1 παρουσίασαν οι ισομορφές της BuChE και ΜΑΟ των εγκεφαλικών ιστών, ανάλογα με τη χορηγούμενη δόση. Αντιχολινεστερασική και αντιοξειδωτική δράση επέδειξαν τόσο η μακρόχρονη πρόσληψη αφεψήματος κρόκου όσο και η βραχύχρονη i.p. χορήγηση κροκετίνης στους εγκεφαλικούς ιστούς των υγιών μυών, ενώ δεν μετέβαλλαν τη μνημονική τους ικανότητα. Η βραχύχρονη συγχορήγηση εκχυλίσματος κρόκου στο τέλος της περιόδου πρόσληψης AlCl3, αν και δεν είχε καμία επίδραση στη γνωστική ικανότητα των μυών, αντέστρεψε σημαντικά τις επαγόμενες από το Al αλλαγές της ενεργότητας της ΜΑΟ και των επιπέδων MDA και GSH των εγκεφαλικών ιστών. Επιπλέον, η ενεργότητα των ισομορφών της AChE των εγκεφαλικών ιστών μειώθηκε περαιτέρω σημαντικά μετά τη χορήγηση του εκχυλίσματος. HPLC ανάλυση του ολικού εγκεφάλου (-ce) των μυών αποκάλυψε, για πρώτη φορά στην παρούσα μελέτη, την παρουσία κροκετίνης μετά τη βραχύχρονη συγχορήγηση εκχυλίσματος κρόκου, η οποία δεν ανιχνεύτηκε στους μύες μάρτυρες. Η μακρόχρονη καθημερινή κατανάλωση αφεψήματος κρόκου πριν την έκθεση σε υψηλή δόση AFB1 απέτρεψε την επαγόμενη από τη μυκοτοξίνη μνημονική εξασθένηση, αναστολή της DS-BuChE του ολικού εγκεφάλου (-ce), αύξηση της ενεργότητας της ΜΑΟ-Α του εγκεφάλου και της ΜΑΟ-Β της παρεγκεφαλίδας και οξειδωτική βλάβη των λιπιδίων στους εγκεφαλικούς ιστούς. Επίσης, οι μύες που κατανάλωναν το αφέψημα εμφάνισαν περαιτέρω σημαντική μείωση της ενεργότητας των ισομορφών της AChE του ολικού εγκεφάλου (-ce), της DS-AChE της παρεγκεφαλίδας και των επιπέδων GSH των εγκεφαλικών ιστών. Αν και η βραχύχρονη i.p. χορήγηση καθαρής κροκετίνης πριν ή μετά την έκθεση σε υψηλή δόση AFB1 δεν επηρέασε την ικανότητα μάθησης/μνήμης των μυών, έδρασε αποτελεσματικά στην πρόληψη ή αντιστροφή της επαγόμενης από τη μυκοτοξίνη αναστολής της BuChE του ολικού εγκεφάλου (-ce), ενεργοποίησης των ισομορφών της ΜΑΟ του εγκεφάλου και αύξησης της λιπιδικής υπεροξείδωσης των εγκεφαλικών ιστών. Ωστόσο, μόνο η προηγηθείσα χορήγηση κροκετίνης απέτρεψε την αύξηση της ενεργότητας της ΜΑΟ-Β της παρεγκεφαλίδας και τη μείωση των επιπέδων GSH των εγκεφαλικών ιστών, που προκάλεσε η χορήγηση της AFB1. Διαφορική απόκριση (περαιτέρω αναστολή ή αύξηση) στη χορήγηση κροκετίνης εμφάνισαν οι ισομορφές της AChE των εγκεφαλικών ιστών, ανάλογα με τη χρονική ακολουθία της χορήγησης. ΣΥΜΠΕΡΑΣΜΑ: Τα αποτελέσματα της παρούσας μελέτης δείχνουν ότι η μακρόχρονη πρόσληψη AlCl3 μέσω του πόσιμου νερού και η βραχύχρονη συστημική έκθεση στην AFB1 ασκούν ισχυρές νευροτοξικές επιδράσεις στους ενήλικες μύες, όπως απέδειξαν η επαγωγή μνημονικής εξασθένησης και οι νευροχημικές διαταραχές. Η αναστολή του γνωστικού ελλείμματος από τη μακρόχρονη κατανάλωση αφεψήματος κρόκου, υποστηρίζει τη νευροπροστατευτική δράση του κρόκου έναντι της νευροτοξικότητας της AFB1 και τον αναδεικνύει ως ελπιδοφόρο διατροφικό παράγοντα στην πρόληψη της εγκεφαλικής δυσλειτουργίας. Ωστόσο, οι ευεργετικές επιδράσεις της κροκετίνης στους νευροχημικούς δείκτες της εγκεφαλικής λειτουργίας υπό συνθήκες τοξικότητας και η απόδειξη της βιοδιαθεσιμότητάς της στον εγκέφαλο, προτείνουν τη συμβολή των καροτενοειδών συστατικών του κρόκου στις νευροπροστατευτικές του ιδιότητες και ενθαρρύνουν την περαιτέρω διερεύνησή τους ως νευροπροστατευτικών παραγόντων. / Mammalian brain is quite susceptible to environmental toxins, due to its special structural and functional features. Exposure to a neurotoxin is commonly manifested through cognitive and behavioral disturbances that follow adverse neurochemical changes and are defined by the animal species in question, the age, the gender, the genetic profile, the dose, the route and the period of exposure. However, chronic exposure to a neurotoxic agent may induce irreversible neuronal damage and degeneration. Aluminum (Al), which is the third most abundant element in nature, exerts diverse neurotoxic effects, depending on the metal’s chemical form, the dose, the route and the period of exposure, while its implication in the pathogenesis of Alzheimer’s disease remains controversial. Aflatoxin B1 (AFB1) is classified to the group of mycotoxins (secondary metabolite of the fungi of Aspergillus sp.), contaminates crops and feeds and constitutes potent hepatotoxin and hepatocarcinogen. Nevertheless, AFB1 neurotoxicity is poorly studied and the few reports focus on the manifestation of behavioral disorders after exposure at developmental stage. During the last decades, extensive research on the neuroprotective action of medicinal plants and their bioactive components is carried out, with the aim of prevention or treatment of brain dysfunction that is provoked by genetic and/or environmental agents. The plant Crocus sativus L. is of particular interest in Greece ,due to its large-scale cultivation and the high commercial value of its styles (saffron); saffron is used as a spice in diet and its medicinal properties have been recognized for millenia. The aim of the present study was to contribute to the investigation of the neurotoxic activity of Al and AFB1 and the neuroprotective role of saffron, focusing on aspects of memory function, brain cholinergic/monoaminergic transmission and oxidant/antioxidant state in adult mice. METHODS: Male adult Balb-c mice (n=7-10/group) received either AlCl3 orally (50 mg/kg body weight/day) dissolved in normal drinking water for 5 weeks or AFB1 intraperitoneally (i.p.) (0.3 and 0.6 mg/kg body weight/day) for 4 days. The potential of saffron extracts and crocetin, the main bioactive metabolite of saffron carotenoid constituents (crocins), in prevention or reversal of the detrimental effects of Al and AFB1 on mouse brain, was investigated by adopting the following administration schemes: a) aqueous methanolic extract of saffron (60 mg/kg body weight/day) was administered i.p. for the last 6 days of AlCl3 treatment period (50 mg/kg body weight/day in drinking water for 5 weeks), b) saffron infusion (0.45 mg/mL) was consumed for 2 weeks prior to AFB1 administration (0.6 mg/kg body weight/day i.p. for the last 4 days of saffron infusion treatment period), and c) pure crocetin (4 mg/kg body weight/day) was administered i.p. for 3 days before or after AFB1 administration (0.6 mg/kg body weight/day i.p. for 4 days). The effects of the previous administration schemes of saffron infusion and crocetin on brain of healthy adult mice, were also studied. The learning/memory ability of mice was evaluated by step-through passive avoidance task. The activity of acetylcholinesterase [AChE, salt-(SS)/detergent-soluble (DS) isoforms], butyrylcholinesterase (BuChE, SS/DS isoforms) and monoamine oxidase (MAO, -A and -B isoforms) was assessed in whole brain (-ce, minus cerebellum) and cerebellum, as indices of cholinergic and monoaminergic transmission, respectively. Moreover, malondialdehyde (MDA) and reduced glutathione (GSH) concentrations were determined as indices of lipid peroxidation and antioxidant defence, respectively, in cerebral tissues. Cerebral tissues’ Al levels were measured by atomic absorption spectrometry, while, for the first time, crocetin was determined in mouse whole brain (-ce) after i.p. administration of saffron extract by HPLC analysis. RESULTS: Long-term intake of high dose of AlCl3 through drinking water resulted in learning/memory impairment of mice, significant reduction of AChE and BuChE activity, increase of MAO isoforms’ activity in whole brain (-ce), but inhibition of cerebellar MAO-B, significant elevation of brain MDA levels and decrease of GSH content in cerebral tissues. Metal accumulation was recorded in brain tissues of AlCl3 treated mice. Mice receiving high (0.6 mg/kg) but not low dose (0.3 mg/kg) of AFB1 displayed memory deficit. Furthermore, short-term i.p. administration of mycotoxin inhibited cholinesterases (ChEs), activated MAO, increased significantly lipid peroxidation and reduced GSH levels in cerebral tissues. However, brain tissues’ BuChE and MAO isoforms presented differential response to AFB1 exposure, depending on the administered dosage. Both long-term saffron infusion intake and short-term i.p. administration of crocetin exerted anti-cholinesterase and antioxidant action in healthy mice’ cerebral tissues, while their memory performance remained unchanged. Although short-term co-administration of saffron extract at the end of AlCl3 treatment period had no effect on cognitive capacity of mice, it reversed significantly the Al-induced changes in MAO activity and the levels of MDA and GSH of cerebral tissues. Moreover, cerebral AChE isoforms’ activity was further significantly decreased following saffron extract co-administration. HPLC analysis of mouse whole brain (-ce) revealed, for the first time, the presence of crocetin after short-term saffron extract co-administration, which was not detected in control mice. Long-term daily consumption of saffron infusion prior to AFB1 (high dose) exposure prevented the mycotoxin-induced memory impairment, inhibition of whole brain (-ce) DS-BuChE, increase of brain MAO-A and cerebellar MAO-B activity, and oxidative damage of lipids in brain tissues. Also, saffron infusion pre-treated mice displayed further significant decrease of the activity of AChE isoforms in whole brain (-ce), DS-AChE in cerebellum and the levels of GSH in cerebral tissues. Although, short-term i.p. administration of pure crocetin before or after AFB1 (high dose) exposure had no effect on learning/memory ability of mice, it effectively prevented or reversed the mycotoxin-induced inhibition of whole brain (-ce) BuChE, activation of brain MAO isoforms and elevation of cerebral tissues’ lipid peroxidation. However, only crocetin pre-treatment inhibited the increase of cerebellar MAO-B activity and reduction of brain tissues’ GSH content which were provoked by AFB1 administration. Cerebral tissues’ AChE isoforms presented differential response (further decrease or increase) to crocetin treatment, depending on time course of administration. CONCLUSION: The findings of the present study show that long-term intake of AlCl3 through drinking water and short-term systemic exposure to AFB1, exert strong neurotoxic effects on adult mice, as evidenced by the induction of memory impairment and the neurochemical disturbances. The inhibition of cognitive deficit by long-term saffron infusion consumption supports its neuroprotective action against AFB1 neurotoxicity and highlights saffron as a promising dietary agent in prevention of brain dysfunction. However, the beneficial effects of crocetin on neurochemical indices of brain function under toxicity and the demonstration of its bioavailability in brain, suggest the contribution of saffron carotenoids in saffron’s neuroprotective properties and encourage their further investigation as neuroprotective agents.

Purpose Monoamine oxidase (MAO) consists of two isoforms, namely MAO-A and MAO-B. Both these isoforms are involved in the oxidation of dopamine. In Parkinson’s disease (PD) therapy, the inhibition of the oxidation of dopamine by MAO may elevate the levels of dopamine in the brain and prevent the generation of toxic by-products such as hydrogen peroxide. MAO-B inhibitors have found application as monotherapy in PD and it has been shown that MAO-B inhibitors may also be useful as adjuvants to L-dopa in PD therapy. For example, an earlier study has shown that the combination of L-dopa with (R)-deprenyl (a selective MAO-B inhibitor), may lead to a reduction of the dose of L-dopa required for alleviating the motor symptoms in PD patients. However, older MAO inhibitors may possess adverse side effects such as psychotoxicity, liver toxicity and cardiovascular effects. The irreversible mode of inhibition of the older MAO-B inhibitors, such as (R)-deprenyl, may also be considered as less desirable. After the use of irreversible inhibitors, it may require several weeks for the MAO enzyme to recover activity. In contrast, after administration of a reversible inhibitor, enzyme activity is recovered as soon as the inhibitor is cleared form the tissues. The adverse effects and disadvantages of the older MAO-B inhibitors prompted us to undertake the discovery of safer and reversible inhibitors of MAO-B. Such compounds may find application in the treatment of PD. Rationale It was recently discovered that (E)-8-(3-chlorostyryl)caffeine (CSC) is a potent inhibitor of MAO-B, with an IC50 value of 0.128 µM. CSC has a caffeine moiety, which is thought to be essential for MAO-B inhibition. It was also reported that a related series of 8- (phenoxymethyl)caffeine derivatives are potent and reversible inhibitors of MAO-A and –B. The IC50 values of the 8-(phenoxymethyl)caffeines ranged from 0.148–5.78 µM for the inhibition of MAO-B. For the purpose of this study the phenoxymethyl side-chain was replaced with a phenylsulfanyl moiety at C8. The aim of this study was therefore to synthesize a series of 8-[(phenylsulfanyl)methyl]caffeine analogues and to compare their MAO-B inhibition potencies to the previously synthesised 8-(phenoxymethyl)caffeine derivatives. A series of five 8-[(phenylsulfanyl)ethyl]caffeine analogues was also synthesized in order to determine the effect of carbon chain elongation on the potency of MAO inhibition. O C-8 N N O N N Caffeine Cl O N N (E) O N N CSC O N N O O N N 8-(Phenoxymethyl)caffeine O N N O N N S 8-[(Phenylsulfanyl)methyl]caffeine O N N S O N N 8-[(Phenylsulfanyl)ethyl]caffeine Compound R1 R2 1a H H 1b Cl H 1c Br H 1d F H 1e CH3 H 1f OCH3 H 1g OCH2CH3 H 1h H Cl 1i H Br Compound R1 R2 2a H H 2b Cl H 2c Br H 2d H Cl 2e H Br Methods The C8 substituted caffeine analogues were synthesised by reacting 1,3-dimethyl-5,6-diaminouracil with an appropriately substituted 2-(phenylsulfanyl)acetic acid or 3-(phenylsulfanyl)propanoic acid in the presence of a carbodiimide activating reagent, N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (EDAC). Ring closure of the intermediary amide was effected by reaction with sodium hydroxide. Resulting theophylline analogues were subsequently methylated in the presence of iodomethane to yield the target compounds. The structures of the C8 substituted caffeine analogues were verified by NMR and MS analysis. The purities thereof were subsequently estimated by HPLC analysis. The 8-[(phenylsulfanyl)methyl]caffeine and 8-[(phenylsulfanyl)ethyl]caffeine analogues were evaluated as MAO-A and –B inhibitors. The recombinant human enzymes were used as enzyme sources. The inhibitory potencies of the caffeine derivatives were expressed as IC50 values (the concentration of a drug that is required for 50% inhibition in vitro). The time- dependency of inhibition of MAO-B by the most potent inhibitor was also evaluated in order to determine the reversibility of inhibition of the test compound. A study was also conducted to determine the inhibition mode of the most potent test compound, by constructing a set of Lineweaver Burk plots. Results The results showed that the 8-[(phenylsulfanyl)methyl]caffeine analogues were inhibitors of MAO-A and –B. The most potent inhibitor in the first series (1a–i) of this study were 8-[(3- bromophenylsulfanyl)methyl]caffeine and 8-[(4-bromophenylsulfanyl)methyl]caffeine with IC50 values of 4.90 and 4.05 µM, respectively. When these results were compared to those of the previously studied 8-(phenoxymethyl)caffeine derivatives it was found that, for these compounds, the bromine substituted homologues were also the most potent MAO-B inhibitors. The bromine substituted 8-(phenoxymethyl)caffeine derivatives exhibited IC50 values of 0.148 and 0.189 µM for those homologues containing bromine on the meta and para positions of the phenoxy side chain, respectively. In general, the 8- [(phenylsulfanyl)methyl]caffeine derivatives were found to be less potent MAO-B inhibitors than the 8-(phenoxymethyl)caffeine derivatives. The 8-[(phenylsulfanyl)methyl]caffeine derivatives also did not show as high a degree of selectivity for MAO-B (compared to MAO- A) as did the 8-(phenoxymethyl)caffeines. Similar to the 8-(phenoxymethyl)caffeines, the 8- [(phenylsulfanyl)methyl]caffeines also proved to be weak MAO-A inhibitors. The most potent inhibitor of MAO-A among the test compounds exhibited an IC50 value of 19.4 µM. The most potent MAO-A inhibitor among the previously studied 8-(phenoxymethyl)caffeines was more potent with an IC50 value of 4.59 µM. From these results it may be concluded that the phenoxy side chain is more suited for the design of caffeine derived MAO inhibitors than the phenylsulfanyl side chain. The results for the second series investigated in this study, the 8-[(phenylsulfanyl)ethyl]caffeines (2a–e), revealed the chlorine substituted derivatives to be the most potent MAO-B inhibitors. The meta and para chlorine substituted derivatives exhibited IC50 values of 5.67 and 7.79 µM, respectively, for the inhibition of MAO-B. Interestingly, the meta substituted derivative exhibited no inhibition toward the MAO-A isoenzyme. However, the 8-[(phenylsulfanyl)ethyl]caffeine derivatives were found to be very weak inhibitors of both MAO-A and –B and may be considered as less potent than the 8-[(phenylsulfanyl)methyl]caffeine derivatives. Since one of the aims of this study was to synthesise reversible MAO inhibitors, a time- dependency study was carried out with the best inhibitor (1i). The aim of this study was to determine the reversibility of inhibition by the 8-[(phenylsulfanyl)methyl]caffeine derivatives. From the results, it was concluded that the inhibition of MAO-B by compound 1i is reversible. To determine the mode of inhibition, a set of Lineweaver-Burk plots was constructed and since the plots were linear and intersected on the y-axis, it was concluded that 1i is a competitive inhibitor of MAO-B. Conclusion This study concludes that the phenoxymethyl side-chain is more suited for the design of caffeine derived MAO-B inhibitors than the (phenylsulfanyl)methyl side-chain. / Thesis (MSc (Pharmaceutical Chemistry))--North-West University, Potchefstroom Campus, 2013.

Purpose Monoamine oxidase (MAO) consists of two isoforms, namely MAO-A and MAO-B. Both these isoforms are involved in the oxidation of dopamine. In Parkinson’s disease (PD) therapy, the inhibition of the oxidation of dopamine by MAO may elevate the levels of dopamine in the brain and prevent the generation of toxic by-products such as hydrogen peroxide. MAO-B inhibitors have found application as monotherapy in PD and it has been shown that MAO-B inhibitors may also be useful as adjuvants to L-dopa in PD therapy. For example, an earlier study has shown that the combination of L-dopa with (R)-deprenyl (a selective MAO-B inhibitor), may lead to a reduction of the dose of L-dopa required for alleviating the motor symptoms in PD patients. However, older MAO inhibitors may possess adverse side effects such as psychotoxicity, liver toxicity and cardiovascular effects. The irreversible mode of inhibition of the older MAO-B inhibitors, such as (R)-deprenyl, may also be considered as less desirable. After the use of irreversible inhibitors, it may require several weeks for the MAO enzyme to recover activity. In contrast, after administration of a reversible inhibitor, enzyme activity is recovered as soon as the inhibitor is cleared form the tissues. The adverse effects and disadvantages of the older MAO-B inhibitors prompted us to undertake the discovery of safer and reversible inhibitors of MAO-B. Such compounds may find application in the treatment of PD. Rationale It was recently discovered that (E)-8-(3-chlorostyryl)caffeine (CSC) is a potent inhibitor of MAO-B, with an IC50 value of 0.128 µM. CSC has a caffeine moiety, which is thought to be essential for MAO-B inhibition. It was also reported that a related series of 8- (phenoxymethyl)caffeine derivatives are potent and reversible inhibitors of MAO-A and –B. The IC50 values of the 8-(phenoxymethyl)caffeines ranged from 0.148–5.78 µM for the inhibition of MAO-B. For the purpose of this study the phenoxymethyl side-chain was replaced with a phenylsulfanyl moiety at C8. The aim of this study was therefore to synthesize a series of 8-[(phenylsulfanyl)methyl]caffeine analogues and to compare their MAO-B inhibition potencies to the previously synthesised 8-(phenoxymethyl)caffeine derivatives. A series of five 8-[(phenylsulfanyl)ethyl]caffeine analogues was also synthesized in order to determine the effect of carbon chain elongation on the potency of MAO inhibition. O C-8 N N O N N Caffeine Cl O N N (E) O N N CSC O N N O O N N 8-(Phenoxymethyl)caffeine O N N O N N S 8-[(Phenylsulfanyl)methyl]caffeine O N N S O N N 8-[(Phenylsulfanyl)ethyl]caffeine Compound R1 R2 1a H H 1b Cl H 1c Br H 1d F H 1e CH3 H 1f OCH3 H 1g OCH2CH3 H 1h H Cl 1i H Br Compound R1 R2 2a H H 2b Cl H 2c Br H 2d H Cl 2e H Br Methods The C8 substituted caffeine analogues were synthesised by reacting 1,3-dimethyl-5,6-diaminouracil with an appropriately substituted 2-(phenylsulfanyl)acetic acid or 3-(phenylsulfanyl)propanoic acid in the presence of a carbodiimide activating reagent, N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (EDAC). Ring closure of the intermediary amide was effected by reaction with sodium hydroxide. Resulting theophylline analogues were subsequently methylated in the presence of iodomethane to yield the target compounds. The structures of the C8 substituted caffeine analogues were verified by NMR and MS analysis. The purities thereof were subsequently estimated by HPLC analysis. The 8-[(phenylsulfanyl)methyl]caffeine and 8-[(phenylsulfanyl)ethyl]caffeine analogues were evaluated as MAO-A and –B inhibitors. The recombinant human enzymes were used as enzyme sources. The inhibitory potencies of the caffeine derivatives were expressed as IC50 values (the concentration of a drug that is required for 50% inhibition in vitro). The time- dependency of inhibition of MAO-B by the most potent inhibitor was also evaluated in order to determine the reversibility of inhibition of the test compound. A study was also conducted to determine the inhibition mode of the most potent test compound, by constructing a set of Lineweaver Burk plots. Results The results showed that the 8-[(phenylsulfanyl)methyl]caffeine analogues were inhibitors of MAO-A and –B. The most potent inhibitor in the first series (1a–i) of this study were 8-[(3- bromophenylsulfanyl)methyl]caffeine and 8-[(4-bromophenylsulfanyl)methyl]caffeine with IC50 values of 4.90 and 4.05 µM, respectively. When these results were compared to those of the previously studied 8-(phenoxymethyl)caffeine derivatives it was found that, for these compounds, the bromine substituted homologues were also the most potent MAO-B inhibitors. The bromine substituted 8-(phenoxymethyl)caffeine derivatives exhibited IC50 values of 0.148 and 0.189 µM for those homologues containing bromine on the meta and para positions of the phenoxy side chain, respectively. In general, the 8- [(phenylsulfanyl)methyl]caffeine derivatives were found to be less potent MAO-B inhibitors than the 8-(phenoxymethyl)caffeine derivatives. The 8-[(phenylsulfanyl)methyl]caffeine derivatives also did not show as high a degree of selectivity for MAO-B (compared to MAO- A) as did the 8-(phenoxymethyl)caffeines. Similar to the 8-(phenoxymethyl)caffeines, the 8- [(phenylsulfanyl)methyl]caffeines also proved to be weak MAO-A inhibitors. The most potent inhibitor of MAO-A among the test compounds exhibited an IC50 value of 19.4 µM. The most potent MAO-A inhibitor among the previously studied 8-(phenoxymethyl)caffeines was more potent with an IC50 value of 4.59 µM. From these results it may be concluded that the phenoxy side chain is more suited for the design of caffeine derived MAO inhibitors than the phenylsulfanyl side chain. The results for the second series investigated in this study, the 8-[(phenylsulfanyl)ethyl]caffeines (2a–e), revealed the chlorine substituted derivatives to be the most potent MAO-B inhibitors. The meta and para chlorine substituted derivatives exhibited IC50 values of 5.67 and 7.79 µM, respectively, for the inhibition of MAO-B. Interestingly, the meta substituted derivative exhibited no inhibition toward the MAO-A isoenzyme. However, the 8-[(phenylsulfanyl)ethyl]caffeine derivatives were found to be very weak inhibitors of both MAO-A and –B and may be considered as less potent than the 8-[(phenylsulfanyl)methyl]caffeine derivatives. Since one of the aims of this study was to synthesise reversible MAO inhibitors, a time- dependency study was carried out with the best inhibitor (1i). The aim of this study was to determine the reversibility of inhibition by the 8-[(phenylsulfanyl)methyl]caffeine derivatives. From the results, it was concluded that the inhibition of MAO-B by compound 1i is reversible. To determine the mode of inhibition, a set of Lineweaver-Burk plots was constructed and since the plots were linear and intersected on the y-axis, it was concluded that 1i is a competitive inhibitor of MAO-B. Conclusion This study concludes that the phenoxymethyl side-chain is more suited for the design of caffeine derived MAO-B inhibitors than the (phenylsulfanyl)methyl side-chain. / Thesis (MSc (Pharmaceutical Chemistry))--North-West University, Potchefstroom Campus, 2013.

Purpose: Monoamine oxidase (MAO) plays a key role in the treatment of Parkinson‟s disease (PD), since it is the major enzyme responsible for the catabolism of dopamine in the substantia nigra of the brain. Inhibition of MAO-B may conserve dopamine in the brain and provide symptomatic relief. The MAO-B inhibitors that are currently used for the treatment of PD, are associated with a variety of adverse effects (psychotoxic and cardiovascular effects) along with additional disadvantages such as irreversible inhibition of the enzyme. Irreversible inhibition may be considered a disadvantage, since following treatment with irreversible inhibitors, the rate by which the enzyme activity is recovered may be variable and may require several weeks. In contrast, following the administration of reversible inhibitors, enzyme activity is recovered when the inhibitor is cleared from the tissues. There exists therefore, a need to develop new reversible inhibitors of MAO-B which are considered to be safer than irreversible MAO-B inhibitors. Rationale: Recently discovered reversible MAO-B inhibitors include safinamide and (E)-8-(3-chlorostyryl)caffeine (CSC). Safinamide has a benzyloxy side chain, which is thought to be important for inhibition of MAO-B. CSC, on the other hand, consists of a caffeine moiety with a styryl substituent at C-8, which is also a critical feature for its inhibitory activity. In a previous study, the caffeine ring and the benzyloxy side chain were combined to produce a series of 8-benzyloxycaffeine analogues which proved to be potent new MAO-B inhibitors. In this study, caffeine was substituted with the phenoxymethyl functional group at C-8, instead of the benzyloxy moiety. The aim of this study was therefore to compare the MAO-B inhibition potencies of selected 8-(phenoxymethyl)caffeine analogues with the previously studied 8-benzyloxycaffeine analogues. In the current study, 8-(phenoxymethyl)caffeine (1) and nine 8-(phenoxymethyl)caffeine analogues (2-10) were synthesized and evaluated as inhibitors of recombinant human MAOA and –B. These analogues only differed in substitution on C3 and C4 of the phenoxymethyl phenyl ring. The substituents that were selected were halogens (Cl, F, and Br), the methyl group, the methoxy group and the trifluoromethyl group. These substituents are similar to those selected in a previous study where 8-benzyloxycaffeine analogues were evaluated as MAO inhibitors. This study therefore explores the effect that a variety of substituents on C3 and C4 of the phenoxymethyl phenyl ring will have on the MAO-A and –B inhibition potencies of 8-(phenoxymethyl)caffeine. Based on the results, additional 8-(phenoxymethyl)caffeine analogues with improved MAO-A and –B inhibition potencies will be proposed for investigation in future studies. Methods: The target, 8-(phenoxymethyl)caffeine, analogues were synthesized by reacting 1,3- dimethyl-5,6-diaminouracil with the appropriately substituted phenoxyacetic acid in the presence of a carbodiimide coupling agent. Ring closure was catalyzed in basic conditions and methylation of the resulting theophyline intermediates at C-7 was carried out with iodomethane. The structures and purities of all the target compounds were verified by NMR, MS and HPLC analysis. All of the 8-(phenoxymethyl)caffeine analogues were subsequently evaluated as MAO-A and –B inhibitors using the recombinant human enzymes. The inhibition potencies of the analogues were expressed as the IC50 values (concentration of the inhibitor that produces 50% inhibition). In addition, the time-dependency of inhibition of both MAO-A and –B was evaluated for two inhibitors in order to determine if these inhibitors interact reversibly or irreversibly with the MAO isozymes. A Hansch-type quantitative structure-activity relationship (QSAR) study was carried out in order to quantify the effect that different substituents on the phenyl ring of the 8-(phenoxymethyl)caffeine analogues have on MAO-B inhibition activity. Results: The results showed that among the test compounds, several analogues potently inhibited human MAO-B. The most potent inhibitor was 8-(3-bromophenoxymethyl)caffeine with an IC50 value of 0.148 μM toward human MAO-B. There were also inhibitors which displayed inhibition activities towards human MAO-A with IC50 values ranging from 4.59 μM to 34.0 μM. Compared to the 8-benzyloxycaffeine analogues, that were in general non-selective inhibitors, the 8-(phenoxymethyl)caffeine analogues, evaluated here, were selective for MAO-B. For example, 8-(3-bromophenoxymethyl)caffeine was found to be 141 fold more selective as an inhibitor of MAO-B than of MAO-A. Also, compared to the 8-benzyloxycaffeine analogues, the 8-(phenoxymethyl)caffeine analogues were slightly less potent MAO-B inhibitors. For example, 8-benzyloxycaffeine is reported to have an IC50 value of 1.77 μM for the inhibition of human MAO-B while 8-(phenoxymethyl)caffeine was found to have an IC50 value of 5.78 μM for the inhibition of human MAO-B. This study also shows that two selected analogues bind reversibly to MAO-A and –B, respectively, and that the mode of MAO-B inhibition is competitive for one representative compound. Qualitative inspection of the results revealed interesting structure-activity relationships. For the 8-(phenoxymethyl)caffeine analogues, bearing both the C3 and C4 substituents on the phenyl ring, the MAO-B activity significantly increases with halogen substitution. Furthermore, increased MAO-B inhibition was observed with increased electronegativity of the halogen substituent. To quantify these apparent relationships, a Hansch-type QSAR study was carried out. The results showed that the logarithm of the IC50 values (logIC50) correlated with Hansch lipophilicity (π) and the Swain-Lupton electronic (F) constants of the substituents at C-3 of the phenoxymethyl ring. The correlation exhibited an R2 value of 0.87 and a statistical F value of 13.6. From these results it may be concluded that electron-withdrawing substituents at C3 with a high degree of lipophilicity enhance MAO-B inhibition potency. These results are similar to those previously obtained for the series of 8-benzyloxycaffeine analogues. For this series, the MAO-B inhibition potencies correlated with the Hansch lipophilicity (π) and Hammett electronic (σ) constants of the substituents at C-3 of the benzyloxy ring. Similarly to the 8-(phenoxymethyl)caffeine analogues, electron-withdrawing substituents with a high degree of lipophilicity also enhance the MAO-B inhibition potencies of 8-benzyloxycaffeine analogues. / Thesis (M.Sc. (Pharmaceutical Chemistry))--North-West University, Potchefstroom Campus, 2011

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior / The Silymarin is a flavonolignan complex isolated from milk thistle seeds of Silybum marianum being used in the treatment of injury related to oxidative stress, including liver and neurological diseases, as Parkinson disease. Although silymarin has been reported to possess a variety of pharmacological properties including anti-inflammatory, anticarcinogenic and neuroprotective effects, information regard its antimicrobial and drug modulator potential against microbial resistance is scanty in the literature. In addition, the possible involvement of antioxidant activity in its neuroprotective effect, and on the activity of important enzymes of the central nervous system (i.e., Na+/K+-ATPase and monoamine oxidase (MAO)) have not yet been completely elucidated. Therefore, the objective of this study was to investigate the effect of silymarin on the activity of the enzymes Na+/K+-ATPase and MAO as well as its ability in to modulate the action of antimicrobials in vitro. The results demonstrated that silymarin scavenged the DPPH (2,2-diphenyl-1-picrylhydrazyl) radical and, also reduced significantly the Fe2+ (10 μM) and SNP (sodium nitroprusside, 5 μM) induced lipid peroxidation in rat brain homogenate. Silymarin protected against the oxidation of thiol groups (protein and non-protein) induced by the pro-oxidants, and avoided the reduction in the activity of catalase caused by pro-oxidants at a concentration of 30 μg/mL. The incubation of different concentrations of silymarin increased the activity of Na+/K+-ATPase enzyme and reduced the activity of the enzymes MAO-A and MAO-B. However, the inhibition of MAO-B was more pronounced. The evaluation of the kinetic parameters demonstrated that Silymarin did not alter significantly the Km values for MAO-A and MAO-B, but caused a decrease in Vmax values for both isoforms of the enzyme. With regard to the antimicrobial activity, silymarin and its major active constituent silybin, did not demonstrate antibacterial and antifungal activities not relevant from a clinical point of view (with values of MIC - minimal inhibitory concentration- > 500 μg/mL). However, silybin showed clinically significant antibacterial activity against Escherichia coli with MIC/8 = 64 μg/mL. The combination of sylimarin and silybin demonstrated synergistic activity modulating the efficacy of antibiotics drugs (amikacin, gentamicin, ciprofloxaxin ou imipenem) or antifungal (mebendazole ou nystatin), particularly from the class of aminoglycosides, against multiresistant strains Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus. However, silybin antagonized the antibacterial effect of gentamicin and imipenem against P. aeruginosa. Similarly, silymarin and silybin had antagonistic effect with nystatin against Candida albicans, Candida tropicalis and Candida kruzei. In conclusion, the results showed that silymarin alters the activities of Na+/K+-ATPase and monoamine oxidase, indicating that its neuroprotective effect is not only associated to its antioxidant capacity. The potential of silymarin and silybin to modulate the effects of the drugs suggests an alternative to control bacterial infections caused by antibiotics resistance. / A Silimarina é um complexo de flavonolignanas isolado das sementes de Silybum marianum, sendo utilizada no tratamento de distúrbios relacionados ao estresse oxidativo, incluindo hepatopatias e doenças neurológicas, como a Doença de Parkinson. Embora a silimarina seja referida por possuir uma variedade de propriedades farmacológicas, incluindo efeitos anti-inflamatório, anticancerígeno e neuroprotetor, informações sobre o seu potencial antimicrobiano e modulador de fármacos contra a resistência microbiana são escassas na literatura. Além disso, o possível envolvimento da ação antioxidante no seu efeito neuroprotetor, e sobre a atividade de enzimas importantes do Sistema Nervoso Central (como a Na+/K+-ATPase e a monoamina oxidase - MAO), ainda não foi completamente elucidado. Portanto, o objetivo deste estudo foi investigar o efeito da silimarina na atividade das enzimas Na+/K+-ATPase e MAO bem como a sua capacidade de modular a ação de antimicrobianos in vitro. Os resultados demonstraram que a silimarina sequestrou o radical DPPH (2,2-difenil-1-picrilidrazina) e também reduziu significativamente a peroxidação lipídica em homogeneizado de cérebro de ratos induzida por nitroprussiato de sódio (5 M) e Fe+2 (10 M). A silimarina protegeu contra a oxidação dos grupos tióis proteicos (e não proteicos) induzida pelos pró-oxidantes e evitou a diminuição na atividade da catalase causada pelos pró-oxidantes, na concentração de 30 g/mL. A incubação de diferentes concentrações de silimarina aumentou a atividade da enzima Na+/K+-ATPase e reduziu a atividade das enzimas MAO-A e MAO-B. No entanto, a inibição da MAO-B foi mais pronunciada. A avaliação dos parâmetros cinéticos demonstrou que a silimarina não alterou de forma significativa os valores de Km para a MAO-A e MAO-B, mas causou diminuição nos valores de Vmax para as duas isoformas da enzima. No que diz respeito à atividade antimicrobiana, a silimarina e o seu principal componente ativo, a silibinina, não demonstraram atividade antibacteriana e antifúngica clinicamente relevante (com valores de CIM - concentração inibitória mínima superiores a 500 μg/mL). No entanto, a silibinina apresentou atividade antibacteriana clinicamente significativa contra Escherichia coli com CIM/8 de 64 μg/mL. A combinação de silibinina ou silimarina demonstrou efeito sinérgico modulando a eficácia de fármacos antibióticos (amicacina, gentamicina, ciprofloxaxino ou imipenem) ou antifúngicos (mebendazol ou nistatina) particularmente da classe dos aminoglicosídeos, contra as cepas multirresistentes de E. coli, Pseudomonas aeruginosa e Staphylococcus aureus. No entanto, a silibinina antagonizou o efeito antibacteriano da gentamicina e do imipenem contra P. aeruginosa. Da mesma forma, a silimarina e a silibinina tiveram efeito antagônico com a nistatina contra Candida albicans, Candida tropicalis e Candida kruzei. Em conclusão, os resultados mostraram que a silimarina altera as atividades da Na+/K+-ATPase e MAO, indicando que o seu efeito neuroprotetor não está apenas associado à sua capacidade antioxidante. O potencial da silimarina e da silibinina para modular o efeito de fármacos antimicrobianos sugere uma alternativa para o controle das infecções bacterianas provocadas pela resistência aos antibióticos.